A patient receiving the immune checkpoint inhibitor pembroli…

A patient receiving the immune checkpoint inhibitor pembrolizumab (Keytruda) for metastatic melanoma develops shortness of breath, fatigue, and a persistent cough. The nurse recognizes that these symptoms may indicate which immune-related adverse effect of immunotherapy?